ArticleThoracic cancer2026
Immune-Mediated Multilineage Cytopenias in Thymoma: A Retrospective Case Series.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune-Mediated Multilineage Cytopenias in Thymoma: A Retrospective Case Series.Thoracic cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThymoma is associated with diverse immune abnormalities, yet immune-mediated multilineage cytopenias are exceedingly rare and poorly defined. Their clinical features, immunologic patterns, and treatment outcomes remain unclear.
methodsWe retrospectively reviewed four adult patients with histologically confirmed thymoma and immune-mediated cytopenias affecting ≥ 2 hematopoietic lineages at a tertiary hematology center. Clinical data, bone marrow morphology, immunologic studies, T-cell receptor (TCR) clonality, cytogenetics, next-generation sequencing (NGS), treatments, and outcomes were collected. Responses were assessed using standardized criteria for immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and autoimmune neutropenia (AIN).
resultsThe four patients (aged 44-75 years) showed heterogeneous temporal patterns, with cytopenias occurring either before thymoma diagnosis or years after thymectomy. Three had trilineage cytopenia and one had bicytopenia, with combinations of AIHA, ITP, AIN, and pure red cell aplasia. Bone marrow findings ranged from normal cellularity to erythroid aplasia. Two patients demonstrated clonal TCR rearrangement consistent with T-LGL leukemia, and NGS identified mutations including TET1, EP300, and BCORL1. All received immunosuppressive therapy. Neutrophil and platelet counts responded earlier (1-2 months), whereas erythroid recovery was slower. Despite initial responses (2 CR, 2 PR), three patients relapsed and required additional therapy. After 10-84 months of follow-up, one patient remained in CR and three in PR.
conclusionsThymoma-associated multilineage cytopenias are heterogeneous, frequently relapsing, and driven by complex T-cell-mediated immune dysregulation. Comprehensive evaluation and individualized immunosuppressive therapy are essential for management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.